William Blair Comments on Inogen Inc’s Q3 2017 Earnings (INGN)
Inogen Inc (NASDAQ:INGN) – Analysts at William Blair lifted their Q3 2017 earnings per share estimates for Inogen in a research note issued on Thursday. William Blair analyst M. Kaczor now expects that the medical technology company will post earnings per share of $0.33 for the quarter, up from their prior estimate of $0.30. William Blair also issued estimates for Inogen’s FY2017 earnings at $1.23 EPS, Q1 2018 earnings at $0.24 EPS, Q3 2018 earnings at $0.40 EPS, Q4 2018 earnings at $0.33 EPS and FY2018 earnings at $1.39 EPS.
Several other research firms have also commented on INGN. Needham & Company LLC decreased their price target on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating for the company in a research report on Thursday, June 8th. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Sidoti began coverage on shares of Inogen in a research report on Tuesday, April 18th. They set a “neutral” rating and a $79.00 price target for the company. Zacks Investment Research lowered shares of Inogen from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Finally, Stifel Nicolaus increased their price target on shares of Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research report on Wednesday, May 10th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Inogen currently has a consensus rating of “Buy” and a consensus target price of $91.60.
Inogen (INGN) opened at 91.08 on Monday. The company’s 50-day moving average is $94.52 and its 200-day moving average is $80.91. The stock has a market capitalization of $1.87 billion, a PE ratio of 81.47 and a beta of 1.01. Inogen has a 12 month low of $50.11 and a 12 month high of $97.71.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 11.30% and a return on equity of 12.69%. The company had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same period last year, the company posted $0.25 EPS. Inogen’s revenue was up 17.4% on a year-over-year basis.
Several hedge funds have recently added to or reduced their stakes in INGN. Ameriprise Financial Inc. raised its stake in Inogen by 9.6% in the first quarter. Ameriprise Financial Inc. now owns 127,985 shares of the medical technology company’s stock valued at $9,927,000 after buying an additional 11,223 shares during the last quarter. Texas Permanent School Fund raised its position in shares of Inogen by 0.3% in the first quarter. Texas Permanent School Fund now owns 11,712 shares of the medical technology company’s stock valued at $908,000 after buying an additional 37 shares during the last quarter. Comerica Bank raised its position in shares of Inogen by 5.4% in the first quarter. Comerica Bank now owns 17,906 shares of the medical technology company’s stock valued at $1,497,000 after buying an additional 919 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Inogen by 13.6% in the first quarter. BNP Paribas Arbitrage SA now owns 3,091 shares of the medical technology company’s stock valued at $240,000 after buying an additional 370 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of Inogen by 0.4% in the first quarter. First Trust Advisors LP now owns 29,267 shares of the medical technology company’s stock valued at $2,270,000 after buying an additional 114 shares during the last quarter.
In other Inogen news, EVP Alison Bauerlein sold 6,666 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $83.24, for a total transaction of $554,877.84. Following the completion of the sale, the executive vice president now directly owns 25,758 shares of the company’s stock, valued at $2,144,095.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Scott Wilkinson sold 23,437 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $88.06, for a total transaction of $2,063,862.22. Following the sale, the insider now directly owns 54,088 shares of the company’s stock, valued at $4,762,989.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 87,848 shares of company stock valued at $7,831,966. Insiders own 5.31% of the company’s stock.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.